The cost-effectiveness of gemcitabine plus cisplatin chemotherapy versus mitomycin ifosfamide and cisplatin (MIP), etopiside plus cisplatin, and vinorelbine plus cisplatin in the treatment of stages III B and IV non-small cell lung cancer: An Italian perspective (letter)